Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.
Solid Tumor, Adult|Hepatocellular Carcinoma
DRUG: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib
Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment., up to 36 months
Assessing progress free survival, 48 months|Assessing overall survival, Assessing overall time to survival., 48 months
The tumor diameter was measured and the efficacy was evaluated after treatment with Trametinib combined with Everolimus and Lenvatinib.